Cargando…
Clinical Trials for COVID‐19: Can we Better Use the Short Window of Opportunity?
The scientific community has risen to the coronavirus disease 2019 (COVID‐19) challenge, coming up with an impressive list of candidate drugs and vaccines targeting an array of pharmacological and immunological mechanisms. Yet, generating clinical evidence of efficacy and safety of these candidate t...
Autores principales: | Eichler, Hans‐Georg, Cavaleri, Marco, Enzmann, Harald, Scotti, Francesca, Sepodes, Bruno, Sweeney, Fergus, Vamvakas, Spiros, Rasi, Guido |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7272975/ https://www.ncbi.nlm.nih.gov/pubmed/32407539 http://dx.doi.org/10.1002/cpt.1891 |
Ejemplares similares
-
Are Novel, Nonrandomized Analytic Methods Fit for Decision Making? The Need for Prospective, Controlled, and Transparent Validation
por: Eichler, Hans‐Georg, et al.
Publicado: (2019) -
Regulators' Advice Can Make a Difference: European Medicines Agency Approval of Zynteglo for Beta Thalassemia
por: Schuessler‐Lenz, Martina, et al.
Publicado: (2019) -
Randomized Controlled Trials Versus Real World Evidence: Neither Magic Nor Myth
por: Eichler, Hans‐Georg, et al.
Publicado: (2020) -
Earlier is better when treating rheumatoid arthritis: but can we detect a window of opportunity?
por: Bergstra, Sytske Anne, et al.
Publicado: (2020) -
Advanced Therapy Medicinal Products for Rare Diseases: State of Play of Incentives Supporting Development in Europe
por: Farkas, Andreas M., et al.
Publicado: (2017)